Related by context. All words. (Click for frequent words.) 73 Pivotal Phase III 70 Initiate Phase 69 Pivotal Trial 69 Initiates Phase III 69 Phase III Clinical Trial 68 Initiates Phase II 68 Patient Enrollment 68 Completes Patient Enrollment 68 Phase #b/#a clinical 68 Files Investigational 68 phase IIb clinical 68 Phase IIb Trial 68 Granted Orphan Drug 68 Receives Orphan Drug Designation 67 phase IIa clinical 67 LUMINATE 67 octreotide implant 67 Phase 2b Clinical Trial 67 Dyloject TM 67 Initiates Enrollment 67 Iluvien ® 67 EVIZON TM 67 IND Filing 67 Simulect 67 Archexin 67 NDA Submission 67 LUVENIQ 67 SinuNase TM 67 Pivotal Phase 66 Drug Eluting Stent System 66 Phase III Pivotal 66 PDE4 inhibitor 66 FDA Accepts 66 FOLOTYN ® 66 LEVADEX TM 66 Successfully Completes Phase 66 Personalized Immunotherapy 66 Initiates Clinical 66 Elagolix 66 Tezampanel 66 Completes Enrollment 66 CRMD# 66 ThermoDox R 66 Tesamorelin 66 FDA Approvable Letter 66 tiapamil 66 Phase 1b Clinical Trial 66 Ceflatonin R 66 Phase IIb Clinical Trial 66 Anturol TM 66 Pirfenidone 65 Oral Calcitonin 65 BLP# Liposome Vaccine 65 LymphoStat B belimumab 65 Hsp# Inhibitor 65 Pivotal Clinical Trial 65 Meets Primary Endpoint 65 APEX PD 65 acyclovir Lauriad R 65 Phase 2a Clinical Trial 65 Cetrorelix 65 BLA filing 65 oral ridaforolimus 65 Premarket Approval PMA 65 Phase III Trial 65 Cloretazine ® 65 Troxatyl 65 Phase III Clinical Trials 65 Glybera R 65 Fx #A 65 Inhalation Aerosol 65 Cellegesic 65 Phase IIa trials 65 granted Ortec 65 rALLy clinical trial 65 oral prodrug 65 Oracea TM 65 Dose Ranging Study 65 Ketotransdel 65 receptor tyrosine kinase inhibitor 65 IL# PE#QQR 65 Glufosfamide 65 LibiGel ® 65 Bazedoxifene 65 II Clinical Trial 65 Frova ® 65 LHRH antagonist 64 Zelrix 64 Pafuramidine 64 BRILINTA 64 MKC# MKC# PP 64 Cinacalcet HCl 64 unique alkylating agent 64 Initiate Phase II 64 Phase IIb clinical trials 64 Exherin 64 phase III isavuconazole 64 generation purine nucleoside 64 Aflibercept 64 Panzem R 64 Kamada AAT 64 ARRY # 64 PREOS R 64 Phase Ib IIa 64 delivers fluocinolone acetonide FA 64 Files IND 64 CCX# B 64 fosbretabulin 64 ELADUR ™ 64 Phase III HEAT 64 Phase IIb trials 64 Ozarelix 64 miconazole Lauriad R 64 Adjuvant Treatment 64 Study Evaluating 64 Omacetaxine 64 Premarket Approval Application 64 NEBIDO R 64 IIa trial 64 Clinical Trial Results 64 Phase 2b Trial 64 Initiates Phase 64 BEMA TM Fentanyl 64 REG1 Anticoagulation System 64 Trobalt 64 Oral Spray 64 liver resection surgeries 64 Bremelanotide 64 ILUVIEN ® 64 Testosterone MDTS ® 64 Vicriviroc 64 Phase Ib II 64 PNP inhibitor 64 hormone LHRH antagonist 64 Silodosin 64 QRxPharma 64 Nabi HB Intravenous 64 Commences Phase 64 BENLYSTA ® 64 methylnaltrexone bromide 64 acetonide FA 64 pralatrexate injection folate analogue 64 Phase IIIb clinical 64 Talabostat 64 MIST II 64 molecular imaging radiopharmaceutical 64 ZEVALIN ® 64 OMAPRO ™ 64 Vitrasert R 64 PDUFA Date 63 Pulmonary Arterial Hypertension 63 OMNARIS HFA 63 Bicifadine 63 Marketing Authorisation Application 63 XL# anticancer compounds 63 Zingo TM 63 Sapacitabine 63 Microplasmin 63 GTC recombinant form 63 Initiated Phase 63 reslizumab 63 PROVENGE ® 63 antibody MAb 63 IV APAP 63 Augment Injectable 63 Safinamide 63 Pivotal Phase II 63 Phase III confirmatory 63 HuMax TAC 63 HGS# 63 KRN# 63 VIVITROL ® 63 volociximab 63 Qutenza TM 63 PF # [002] 63 Zenvia ™ 63 GATTEX TM 63 PEGylated Fab fragment 63 Commence Phase 63 Multiple Ascending Dose 63 phase IIa 63 Valtropin 63 WX UK1 63 OLpur TM H2H 63 randomized Phase IIb 63 Patient Enrolment 63 cutaneous T 63 Orapred ODT 63 Phase IIB 63 TAXUS Element Paclitaxel Eluting 63 Levoleucovorin 63 Phase Ib study 63 Submits NDA 63 vinorelbine tartrate 63 Allovectin 7 63 Intravitreal 63 Panzem R NCD 63 Bosutinib 63 MelaFind R 63 ALVESCO R 63 Surfaxin LS 63 topical non steroidal 63 Dacogen injection 63 PrevOnco 63 phase IIb 63 autologous cellular immunotherapy 63 pseudobulbar affect PBA 63 HDAC Inhibitor 63 JZP 63 Tarceva TM 63 initiated Phase Ib 63 PANVAC VF 63 Saforis 63 Zensana TM 63 Prostate Cancer Vaccine 63 IND Application 63 liposomal formulation 63 Initiates Clinical Trial 63 GW# [003] 63 MAA submission 63 Marketing Authorization Application 63 including eniluracil ADH 63 generation calcineurin inhibitor 63 Zenpep 63 Phase Ib clinical 62 Metastatic Melanoma 62 Fast Track Status 62 Prestara TM 62 CCR9 antagonist 62 BCG refractory carcinoma 62 Unit Dose Budesonide 62 ADP receptor antagonist 62 balsalazide tablet 62 Investigational Treatment 62 Submits Investigational 62 Loramyc 62 Prospective Randomized 62 LymphoStat B TM 62 Diabetic Macular Edema 62 targeted radiotherapeutic 62 occlusion PAO 62 SUCCEED trial 62 Trial Evaluating 62 Marketing Authorisation Application MAA 62 novel oral anticoagulant 62 Argatroban 62 Phase 2a Trial 62 BLA submission 62 PresbyLens ® 62 Receives CE Marking 62 atypical Hemolytic Uremic Syndrome 62 Sanvar R 62 Zenvia TM 62 lexidronam injection 62 ISO Vorin TM 62 TRANSDUR ™ 62 histamine dihydrochloride 62 IDE Investigational Device Exemption 62 Phase 1b clinical 62 Phase Ib Clinical Trial 62 Cutanea Life Sciences 62 product platforms AZX# 62 RhuDex 62 assessing T DM1 62 Maribavir 62 mGluR5 negative 62 Begins Dosing 62 Lenocta TM 62 Tesetaxel 62 T Pred 62 Resubmission 62 Investigational Device Exemption IDE 62 Ranolazine 62 Phase 2b Study 62 Bezielle 62 Proxinium TM 62 IND Investigational New 62 Ophthotech 62 phase IIb trial 62 successfully commercialize Iluvien 62 YONDELIS 62 Initiate Phase III 62 hypoxia activated prodrug 62 phase Ib clinical 62 MacuSight 62 Gentamicin Surgical Implant 62 Kynapid 62 lucinactant 62 Zensana 62 Indaflex TM 62 evaluating mipomersen 62 POSIDUR TM 62 OvaRex ® MAb 62 seliciclib CYC# 62 Somatuline R Autogel R 62 Completes Patient Enrolment 62 Combination REOLYSIN R 62 SEPET TM 62 phase Ib 62 FDA Approvals 62 First Patient Dosed 62 UPLYSO 62 Friedreich Ataxia FRDA 62 ONCONASE R 62 AAG geldanamycin analog 62 CIP TRAMADOL ER 62 Single Dose 62 Phase 1a clinical 62 registrational Phase 62 Febuxostat 62 Phase III pivotal 62 First Patient Enrolled 62 Bepreve TM 62 histone deacetylase HDAC inhibitor 62 Phase Ib clinical trials 62 LUCASSIN 62 Æterna Zentaris 62 AVAX 62 anticancer compound 62 Randomized Phase II 62 docetaxel Taxotere R 62 Vilazodone 62 Receives Fast Track 62 Phase IIIb 62 Teysuno 62 GALNS 62 herpetic keratitis 62 E1 INT TM 62 HuMax EGFr 62 Somatuline Autogel 62 REMURA 62 supplemental biologics 62 Fabry Disease 62 Retacrit 62 Factor VIIa 62 tezampanel NGX# 62 Severe Sepsis 62 Phase IIb III 62 Hormone Refractory Prostate Cancer 62 Biologic License Application BLA 62 Hedgehog Pathway Inhibitor 62 Drug Candidate 62 Augment TM 62 Pennsaid R 62 RELOVAIR ™ 62 Xyfid TM 62 dextromethorphan quinidine 61 5 HT3 antagonist 61 Phase #b/#a 61 Initiate Clinical Trial 61 miconazole Lauriad ® 61 Iloperidone 61 Brentuximab Vedotin SGN 61 Prolongs Survival 61 ZYBRESTAT TM 61 Alfimeprase 61 lintuzumab SGN 61 Omigard TM 61 Extina 61 Fibrin Sealant 61 TBC# 61 Epratuzumab 61 RhuDex ® 61 Civacir 61 RANK Ligand inhibitor 61 IMPACT IMmunotherapy 61 Ceflatonin 61 PGL# 61 Crofelemer budesonide foam 61 SAFLUTAN 61 TM Drug Eluting 61 Telavancin 61 LEUKINE 61 GLP1 INT TM 61 Catena ® 61 FIRMAGON R 61 CONBRIZA 61 Xeloda ® 61 VALSTAR 61 Topotecan 61 Phase 2b clinical trials 61 BRIM2 61 voclosporin 61 Omapro 61 Tanespimycin 61 Investigational Device Exemption 61 forodesine 61 TAXUS Element Stent System 61 Efficacy Results 61 POSIDUR TM ELADUR TM 61 Oral Insulin 61 OvaRex R 61 Serada 61 MKC# MT 61 multicenter Phase 61 Vascular Disrupting Agent 61 Synera 61 NP2 Enkephalin 61 Central Retinal Vein 61 vidofludimus 61 PMA submission 61 IMC #B 61 Mipomersen 61 R#/MEM 61 Vion Pharmaceuticals 61 Degarelix 61 SUTENT ® 61 severe gastroparesis 61 ADVEXIN p# therapy 61 JAK2 Inhibitor 61 Prodarsan 61 Phase Ib 61 ONGLYZA ™ 61 Pivotal Study 61 Ophena TM 61 Clolar ® 61 Phase 1b clinical trials 61 Premarket Approval 61 Randomized Phase 61 overactive bladder AA# 61 2 methoxyestradiol 61 ZOLINZA 61 Romidepsin 61 Release Capsules 61 Receives Approvable Letter 61 Cand5 61 IND submission 61 Orphan Drug status 61 radiation sensitizer 61 urethral bulking agent 61 TRO# 61 Demonstrates Significant 61 highly selective inhibitor 61 Dupuytren Contracture 61 Delcath Phase III 61 Investigational Oral 61 Onrigin 61 MAGE A3 ASCI 61 Phase IIa Clinical Trial 61 Initiates Phase 2b 61 Application BLA 61 BST CarGel R 61 NASDAQ CXSP announced 61 induced macular edema 61 Vascular Wrap TM 61 MelaFind ® 61 dasatinib Sprycel ® 61 PHX# 61 Aerosurf 61 catheter occlusion 61 Announces Tentative Approval 61 Besivance 61 Uvidem 61 Novel Antibiotic 61 PI3K/Akt pathway inhibitor 61 cell lymphoma CTCL 61 Malignant Melanoma 61 docetaxel Taxotere ® 61 eniluracil 61 tezampanel 61 Novolimus 61 Double Blind Placebo 61 Omigard 61 oxymorphone ER 61 cancer neuroendocrine tumor 61 Iluvien TM 61 Accelerated Approval 61 ChemGenex Pharmaceuticals Limited 61 Orphan Drug Status 61 trastuzumab DM1 T DM1 61 EVIZON ™ 61 LEVADEX ™ 61 Myocet 61 Keryx Biopharma 61 ANTEGREN 61 mertansine 61 cetrorelix pamoate 61 Onco TCS 61 Clinical Study Shows 61 Receives Orphan Drug 61 Octreotide 61 Rescula 61 GLP1 agonist 61 Entereg R 61 Traficet EN 61 Bendamustine 61 Genasense ® oblimersen 61 SYCREST 61 Durezol TM 61 TRANSDUR Bupivacaine 61 Zenvia Phase III 61 AVASTIN 61 PrevOnco ™ 61 Fibrin Pad 61 enoximone capsules 61 Investigational Compound 61 REG2 61 Soliris TM eculizumab 61 Ropinirole 61 SinuNase 61 Enzyme Replacement Therapy 61 intravesical infusion therapy 61 Celgosivir 61 Oral Fingolimod 61 dose escalation clinical 61 Matrix Phase 2b 61 registrational trial 61 NVA# 61 Hedgehog antagonist 61 markets HP Acthar 61 Nasdaq PGNX today 61 Announces Poster Presentations 61 Urocidin 61 novel histone deacetylase 61 sodium Injection 61 PROGENSA R 61 pharmacokinetic PK study 61 Targeted Chemotherapy 61 Submits Biologics License Application 61 investigational antiplatelet agent 61 Prodarsan R 61 Corlux 61 Pegloticase 61 vascular disrupting agent 61 PHASE III 61 Confirmatory Phase 61 Initiates Clinical Trials 60 Curaxin CBLC# 60 vapreotide acetate 60 Medidur TM FA 60 Ixempra 60 R#/MEM # 60 Biologic License Application 60 generation rotary VAD 60 Controlled Study 60 Teva Provides Update 60 Sumatriptan Succinate 60 immunotherapeutic vaccine 60 Genasense ® 60 GSK# [001] 60 Loramyc R 60 Polymer Microspheres 60 KRYSTEXXA TM pegloticase 60 Phase III Trials 60 non nucleoside inhibitor 60 Dose Escalation 60 LibiGel Phase III 60 L BLP# 60 Achieves Primary Endpoint 60 Raptiva ® 60 ZACTIMA 60 OMNARIS Nasal Spray 60 FUSILEV ® 60 PROVENGE sipuleucel T 60 StaphVAX R 60 XL# XL# 60 dependent kinase inhibitor 60 Clevudine 60 Dalbavancin 60 Auxilium Pharma 60 DermTech International 60 Evamist TM 60 Acute Decompensated Heart Failure 60 Generic Version 60 SNT MC# 60 Phase III multicenter 60 Phase III PREGNANT PROCHIEVE 60 Amrubicin 60 Motesanib 60 Emezine 60 Phase #b/#a trial 60 Sopherion 60 randomized controlled Phase 60 severe hypercholesterolemia 60 fostamatinib 60 posterior uveitis 60 ezogabine 60 Oracea ® 60 Annamycin 60 Surgical Mesh 60 PDX pralatrexate 60 pivotal bioequivalence 60 placebo controlled Phase 60 Phase III Psoriasis 60 Presents Positive 60 Prestara 60 IgG1 monoclonal antibody 60 orally inhaled migraine 60 Anturol 60 Mycophenolate Mofetil 60 Phase 1b trial 60 Clinical Trial Evaluating 60 subcutaneous formulation 60 Golimumab 60 Ophena 60 VitiGam 60 Zirgan 60 Gout Drug 60 metastatic malignant 60 cetuximab Erbitux R 60 Zybrestat 60 Quinamed 60 SomatoKine 60 OvaRex 60 BiovaxID TM 60 investigational humanized monoclonal antibody 60 Roflumilast 60 TRANSDUR ® 60 Acute Heart Failure 60 Liprotamase 60 Kuvan R 60 Clinuvel 60 signal detection CTSD 60 PFO migraine 60 personalized cellular immunotherapy 60 midstage clinical 60 Evoltra 60 GLP toxicology studies 60 Sanvar 60 generation PNP inhibitor 60 MEND CABG II 60 Aurexis 60 Welichem 60 Cloretazine 60 Ciclesonide 60 Marketing Authorization Application MAA 60 Luramist 60 Romiplostim 60 confirmatory Phase III 60 highly purified pasteurized 60 relapsed refractory multiple myeloma 60 XIAFLEX ™ 60 Cimzia TM 60 Novel Oral 60 CB2 selective receptor agonist 60 Submits Supplemental 60 Torisel 60 oral nucleoside analogue 60 Icatibant 60 SUPPRELIN R LA 60 Topline Results 60 AcelRx 60 Exelixis XL# 60 EOquin TM 60 topically administered 60 estradiol transdermal spray 60 HuMax CD4 60 Diabetic Nephropathy 60 virus HCV protease inhibitor 60 MKC# 60 TLK# 60 SinuNase ™ 60 AEG# 60 telomerase therapeutic 60 Xolegel 60 HepeX B TM 60 Nasdaq HALO 60 initiate Phase IIb 60 zileuton CR 60 Plaque Psoriasis 60 Presents Preclinical Data 60 Complicated Skin 60 PREOS 60 BRIM3 60 NEBIDO 60 evaluating picoplatin 60 Immunotherapeutic 60 Complete Response 60 Orphan Drug designations 60 Expedited Review 60 sNDA submission 60 miconazole MBT 60 Phase III clinical 60 Lubiprostone 60 NasdaqGM NTEC today 60 Ridaforolimus 60 Fast Track Designation 60 Supplemental Biologics License Application 60 Lodotra TM 60 Valortim TM 60 ZYBRESTAT fosbretabulin 60 phase IIb III 60 ruxolitinib 60 myelodysplastic myeloproliferative diseases 60 Cutaneous T 60 BrachySil TM 60 GEM OS2 60 alvimopan 60 Angiocept 60 Phase 2a clinical trials 60 refractory chronic lymphocytic 60 CYT# potent vascular disrupting 60 NGX# 60 nephropathic cystinosis 60 Synta Announces 60 VITAL Trial 60 RNAi Therapeutic 60 HP Acthar Gel repository 60 icatibant 60 MIVI III 60 vemurafenib 60 eprodisate Fibrillex TM 60 Irinotecan 60 Zorbtive TM 60 Vernakalant 60 Orphan Status 60 aldehyde dehydrogenase ALDH2 deficiency 60 injectable enzyme 60 GENERIC SILDENAFIL SOFT Generic 60 Temsirolimus 60 Glatiramer Acetate 60 Phase IIa clinical 60 Phase III psoriasis 60 submit Biologics License 60 Medtronic CoreValve 60 TOCOSOL Paclitaxel 60 Dual Opioid 60 acute peripheral arterial 60 Pyridorin 60 MONOVISC 60 Ocrelizumab 60 Aryplase 60 FDA APPROVES 60 Abstral ® 60 ATryn ® 60 huC# DM4 60 Guanilib 60 Phase 2a clinical 60 octreotide acetate 60 Soft Tissue Sarcoma 60 product candidate Lpathomab 60 JAK inhibitor 60 Aloxi R 60 novel synthetic PEGylated 60 Phase 2a 60 MoxDuo IR 60 TO AVOID PREGNANCY WHILE 60 ozarelix 60 Alzhemed TM 60 topical NSAID 60 leading oral taxane 60 Gabapentin GR 60 Urocortin 2 60 investigational monoclonal antibody 60 zileuton IV 60 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 60 NYSE Amex PTN 60 Keppra ® XR 60 Onsolis 60 ONSOLIS TM 60 Xcellerated T Cells 60 OncoGel 60 RELISTOR ® 60 % uracil topical 60 TRX1 60 TKB# 60 PROMACTA 60 AZILECT R 60 IMPACT DCM clinical 60 Ofatumumab 60 QLT# 60 MEK inhibitor 60 rasagiline tablets 59 Taro Receives 59 Fludara ® 59 R vancomycin hydrochloride 59 painful diabetic neuropathy 59 omacetaxine mepesuccinate 59 Lucanix R 59 Santhera 59 OTCQX QRXPY 59 CUSTOM III 59 TASKi2 59 KYNAPID 59 TACI Ig 59 immunotherapeutic agent 59 allosteric modulator NAM 59 selective A2A adenosine receptor 59 Submits Response 59 Loxapine 59 Efficacy Trial 59 Actemra tocilizumab 59 MOVIPREP R 59 LibiGel testosterone gel 59 CVac 59 TELINTRA 59 Resten NG 59 KYTHERA 59 ATryn R 59 Multicenter Phase 59 Pazopanib 59 initiate Phase IIa 59 Ustekinumab 59 Fortical R 59 oral methylnaltrexone 59 IMA# 59 aurora kinase 59 Aganocide 59 Exelixis compounds 59 Circ Pharma 59 ospemifene 59 subsidiaries visit http:/www.apricusbio.com 59 Cardioxyl Pharmaceuticals 59 SPARLON 59 Daclizumab 59 Rhucin ® recombinant 59 Dabigatran etexilate 59 apricitabine ATC 59 Denufosol 59 Kepivance 59 PRT# 59 Cethromycin 59 Drug Eluting Coronary Stent 59 Pivotal Trials 59 Transdermal System 59 albiglutide 59 polymer platinate 59 novel orally inhaled 59 Randomized Double blind 59 Melphalan 59 PEGylated interferon beta 1a 59 Acute Ischemic Stroke 59 Cardio Vascu Grow 59 KNS # 59 RSD# 59 TNF Tumor Necrosis Factor 59 CIMZIA TM 59 Ambrisentan 59 Pixuvri 59 HCl Tablets 59 Patients Treated With 59 GRN# 59 Oxytrex TM 59 eltrombopag 59 Empatic ™ 59 gets USFDA nod 59 Phase IIa clinical trials 59 Mylan Receives Approval 59 oncolytic virus therapies 59 Ostabolin C 59 interferon beta 1b 59 Ganciclovir 59 peginesatide 59 atacicept 59 Allovectin 7 R 59 rALLy 59 nasal calcitonin product 59 BEMA Granisetron 59 Ceflatonin ® 59 Phase III 59 Nipent R 59 metastatic castrate resistant 59 Spiegelmer ® 59 Anticancer Drug 59 HepeX B 59 HepaSphere 59 XIAFLEX ® 59 Phase 2b clinical 59 Ciclopirox 59 solifenacin succinate 59 Glybera 59 romidepsin 59 Alvesco R 59 Lung Rx 59 vaginally administered lidocaine 59 IND enabling 59 Pliaglis 59 Kinase Inhibitor 59 Acetavance TM intravenous acetaminophen 59 vernakalant hydrochloride 59 huN# DM1 59 initiated Phase 1b 59 Randomized Double Blind 59 ThermoDox ® 59 Pharmacokinetic Study 59 oral salmon calcitonin 59 Intravenous Formulation 59 Exherin TM 59 ongoing Phase 1b 59 Gel repository corticotropin injection 59 TH# [003] 59 Phase IIb kidney transplant 59 Advanced Melanoma 59 Cinryze ™ 59 Octreolin 59 Dasatinib 59 Pralatrexate 59 topical gel formulation 59 registrational 59 nucleoside analog 59 orphan medicinal product 59 VISICOL R 59 IAP inhibitors 59 Arzerra ofatumumab 59 Testosterone MDTS R 59 HCV NS5B polymerase 59 DORIBAX 59 Lysteda 59 Inhalation Solution 59 Biologics License Application BLA 59 Horizant ™ 59 DEXILANT 59 Receives Positive Opinion 59 sodium thiosulfate STS 59 STRIDE PD 59 Hematide ™ 59 Enrolling Patients 59 R roscovitine CDK cyclin 59 Fentanyl TAIFUN R 59 PRN FDA Approves 59 Oncoscience AG 59 Diamyd Medical Diamyd 59 Milestone Payment From 59 lorcaserin Phase 59 Bioral ® 59 Vascugel 59 IIa clinical trials 59 topically applied SEPA 59 Polyphenon ® E 59 Submits IND 59 DU #b 59 SCENESSE ® 59 Sphingomab TM 59 Inhaled Insulin 59 Augment ™ 59 SCIB1 59 Testosterone Gel 59 Vidaza R 59 Liposomal 59 mitogen activated ERK kinase 59 Receives SFDA Approval 59 evaluating carfilzomib 59 BEMA Fentanyl 59 Phenoptin 59 Albugon 59 GATTEX ® 59 HP Acthar R 59 MOZOBIL 59 Voraxaze 59 ATL# [002] 59 Nitazoxanide 59 Naproxcinod 59 Somatuline Depot 59 topical ophthalmic 59 ORENCIA ® 59 Refractory Angina 59 Demonstrates Positive 59 LibiGel ® testosterone gel 59 Cethrin 59 Troxatyl TM 59 GetGoal Phase III 59 Oracea R 59 CYT# QbG# 59 GTC recombinant human 59 novel therapeutic antibodies 59 Phase 2a trial 59 paclitaxel poliglumex 59 Advanced Renal Cell 59 liprotamase 59 EVICEL 59 Cintredekin Besudotox 59 XIENCE V Stent System 59 ADVANCE PD 59 Prednisporin TM 59 Indomethacin 59 Hematological Malignancies 59 oral proteasome inhibitor 59 rilonacept 59 RSD# oral 59 ABILIFY ® 59 CoAxia 59 Second Pivotal Phase 59 candidate AQ4N 59 Phase IIb clinical 59 terlipressin 59 EVIZON TM squalamine lactate 59 compound INCB# 59 Amphotericin B 59 Yondelis ® 59 brivaracetam 59 oxybutynin ATD TM 59 FDA approvable letter 59 castrate resistant prostate cancer 59 Phase 2b study 59 KRYSTEXXA TM 59 ASONEP 59 ICA # 59 HCD# [002] 59 IIa clinical 59 GVAX ® 59 Arpida 59 TELINTRA R 59 Percutaneous Transluminal Coronary Angioplasty 59 IV Busulfex 59 zanolimumab 59 ZEGERID Capsules 59 alvespimycin 59 proprietary transdermal patch 59 sublingual tablets